Feds Survey Home Visits for Moms and Babies: Comment Time
Published Date: 12/12/2025
Notice
Summary
HRSA is asking for public feedback on a new survey to check if home visiting programs for moms and young kids meet updated rules. This affects programs helping families in at-risk communities and aims to keep services effective and evidence-based. Comments are open until January 12, 2026, with no new costs expected for participants.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Home‑Visiting Models Face Eligibility Review
HRSA will survey and assess all home‑visiting models that meet HHS evidence criteria (24 models listed as of November 2025) to see if they also meet MIECHV statutory rules. Models must meet requirements such as being in existence at least 3 years, having rigorous published evaluations (randomized controlled or quasi‑experimental designs), training standards for virtual delivery equivalent to in‑person, and providing at least one in‑person home visit per each 12‑month enrollment; models that do not meet these rules will be ineligible for future use and may only continue through the current performance period, and funding recipients will be expected to propose projects using models approved for future awards.
Model Developers Must Complete 3‑Hour Survey
HRSA will request information from model developers via a standardized survey and developers will have 30 days to respond after receiving the survey. HRSA estimates 24 respondents will each take about 3 hours to complete the survey (total annual burden 72 hours); developers may ask for reconsideration of a negative determination within 15 days and HRSA has 45 days to reassess; HRSA expects no new monetary costs for participants.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17009, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Black Lung Clinics Program Performance Measures
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
2026-16871, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Rural Maternity and Obstetrics Management Strategies Program Data Collection, OMB No. 0915-0394-Revision
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
2026-16396, National Newborn Screening Stakeholder Workgroup
HRSA provides funding to support a national center for newborn screening systems known as the National Center for Newborn Screening Systems Excellence (NBS Excel). In fiscal year 2026, supplemental funding is being provided to NBS Excel to establish a national newborn screening stakeholder workgroup. This workgroup will be a pathway for conditions to be considered and recommended for inclusion in the Recommended Uniform Screening Panel (RUSP) and to discuss national- level issues related to newborn screening. Membership will include representatives from a wide range of newborn screening experts and stakeholders. The award recipient will convene the workgroup and develop findings, reports, and recommendations for HRSA's review and consideration. HRSA will then make recommendations to the Secretary of Health and Human Services, who has final decision-making authority on updates to the RUSP.
2026-16227, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Transforming Pediatrics for Early Childhood Program Performance Measures
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
2026-16054, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Organ Procurement and Transplantation Network Board of Directors and Committee Member Applications and Forms
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
2026-15633, Notice Regarding 340B Rebate Model Pilot Program
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternatives, HRSA is announcing this Pilot, which will implement a rebate approach for a limited set of drugs, and which builds on established and successful rebate programs. ---------------------------------------------------------------------------
Previous / Next Documents
Previous: 2025-22608, Agency Information Collection Activities; Comment Request on Provisional Foreign Tax Credit Agreement
The IRS wants your thoughts on a form that helps people and businesses claim credits for foreign taxes they’ve paid. This is all about making sure the paperwork is clear, useful, and not too much of a hassle. If you have ideas or concerns, send them in by February 10, 2026, so the IRS can keep things running smoothly without extra costs or delays.
Next: 2025-22611, Self-Regulatory Organizations: Long-Term Stock Exchange, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Fee Schedule To Modify the Liquidity Incentive Program
The Long-Term Stock Exchange is updating its fee schedule to change how it rewards traders who help keep the market active and fair. These changes to the Liquidity Incentive Program will start on December 1, 2026, affecting anyone trading certain stocks on LTSE. The goal? To make trading smoother and more attractive by tweaking the money incentives.